Research And Development In Biotechnology (Except Nanobiotechnology) federal obligations in FY2026

What the Biotech R&D (ex. Nano)–FY2026 join is

NAICS 541714 and fiscal year 2026 meet here. $243,697,582.31 is the USAspending.gov obligation sum on the yearlyTrend row that carries both tags. It is not Research And Development In Biotechnology (Except Nanobiotechnology)'s nationwide all-year total of $19,013,172,722.03, not every federal dollar coded to FY2026, and not an outlay register. The packet does not split therapeutic areas, and it excludes nanobiotechnology by NAICS definition. 2,378 is an industry-extract action count: modifications and repeat awards add rows across years. Unique recipients are unpublished. This cell is not a lab census, a named-sponsor roster, or a trial-protocol catalog.

Open /industries/541714/ (NAICS 541714) for the industry table without this FY2026 filter, /fiscal-years/2026/ (FY2026 federal spending) for the year table without this NAICS filter, /industries/ (All industries) for every industry, and /ties/ (All spending ties) for the rest of the join list. Quote those hubs as parents, not as addends to $243,697,582.31. Biotech R&D is not residual scientific consulting (541690). Research codes and consulting codes stay separate.

FY2026 beside the Biotech R&D (ex. Nano) longer book

USAspending labels NAICS 541714 as Research And Development In Biotechnology (Except Nanobiotechnology). That code produced $243,697,582.31 when crossed with fiscal year 2026. The industry-wide 541714 hub does not require a FY2026 filter. The year hub does not require Biotech R&D (ex. Nano). Only this tie applies both filters. The packet does not split therapeutic areas, and it excludes nanobiotechnology by NAICS definition. Do not forecast the rest of FY2026 from this snapshot. The packet has no remaining-year estimate.

Correlation is not causation: FY2026 did not cause $243,697,582.31 by existing as a large or small budget year. The join is 541714 × FY2026 only. This cell is not a lab census, a named-sponsor roster, or a trial-protocol catalog. Do not invent contractors or award recipients to fill the gap. Campaign donations on FEC tables do not fund this USAspending cell; the datasets are separate. Two thousand three hundred seventy-eight industry-extract awards describe 541714 across years, not a FY2026 lab or trial census.

2,378 industry-extract awards are not a FY2026 census

2,378 is the Research And Development In Biotechnology (Except Nanobiotechnology) award-record count published with the industry extract, not a count of FY2026 instruments. Dividing $243,697,582.31 by 2,378 would mix a one-year dollar total with a multi-year row count, so this page does not publish that ratio as a typical invoice. Unique recipients are unpublished. Modifications and multi-year vehicles can add lines without adding vendors. Two thousand three hundred seventy-eight industry-extract awards describe 541714 across years, not a FY2026 lab or trial census. FY2026 figures can be incomplete for the current year, so even the dollar cell may still move.

A moderate parent file makes a program split tempting; the packet still does not supply one. A thin parent file makes a named-facility story tempting; the packet still does not name facilities or contractors. 1.3% of $19,013,172,722.03 is the year share on this packet, not a performance score.

Obligations, not outlays

USAspending.gov records an obligation when the federal government commits funds on an award. $243,697,582.31 is that kind of sum for Research And Development In Biotechnology (Except Nanobiotechnology) in FY2026. Later deobligations, recoveries, or payment schedules can change what leaves the Treasury without this join rewriting itself into a cash register. Assistance and contract awards can share the same NAICS rollup; this packet does not split them. Net obligations can include downward adjustments. This page reports $243,697,582.31 as given.

Treat 2,378 as award records on the industry extract, not unique vendors and not a FY2026 headcount. Do not per-capita or per-recipient the dollar total; those denominators are unpublished. FEC contribution tables do not fund these awards. Sponsor names, protocols, and trial counts are unpublished. Quote NAICS 541714 and FY2026 together.

How to cite Biotech R&D (ex. Nano) in FY2026

Cite USAspending.gov: Research And Development In Biotechnology (Except Nanobiotechnology) (NAICS 541714) obligated $243,697,582.31 in FY2026. Name Research And Development In Biotechnology (Except Nanobiotechnology) and FY2026 together. Keep the obligation word. If /industries/541714/ or /fiscal-years/2026/ has refreshed, prefer the live hub over this snapshot for current rows. The pair is not a lab census, a named-sponsor roster, or a trial-protocol catalog. 1.3% of $19,013,172,722.03 is the industry share on this packet, not a budget score. /industries/ lists other industries; /ties/ indexes other pairs.

Keep Research And Development In Biotechnology (Except Nanobiotechnology), FY2026, $243,697,582.31, and the 2,378-record industry extract together without mixing clocks. Do not add those parents to this cell. Sharing a year with Biotech R&D (ex. Nano) does not mean campaign donations funded these awards, and it does not convert obligations into outlays. This page reports one USAspending yearlyTrend join. Biotech R&D is not residual scientific consulting (541690). Research codes and consulting codes stay separate.

Limits of the 541714 × FY2026 snapshot

Two thousand three hundred seventy-eight industry-extract awards describe 541714 across years, not a FY2026 lab or trial census. Biotech R&D is not residual scientific consulting (541690). Research codes and consulting codes stay separate. A reader who quotes 2,378 as unique companies in FY2026 has left the packet. A reader who treats 1.3% as a hardship or success ranking has added a score the table does not carry. Prefer /industries/541714/ and /fiscal-years/2026/ if the live tables moved. Sponsor names, protocols, and trial counts are unpublished. Quote NAICS 541714 and FY2026 together.

This snapshot holds $243,697,582.31 on the yearlyTrend row and 2,378 on the industry extract. /ties/ is the index, not an addend. Obligations are not outlays. Correlation is not causation. A reader who only quotes $243,697,582.31 without FY2026 and NAICS 541714 has dropped a join side.

Questions

How much Biotech R&D (ex. Nano) spending is obligated in FY2026?

USAspending.gov lists $243,697,582.31 in Research And Development In Biotechnology (Except Nanobiotechnology) (NAICS 541714) obligations for FY2026. That yearlyTrend amount is 1.3% of the industry's $19,013,172,722.03 extract-wide total. It is an obligation join, not an outlay and not every federal dollar in FY2026. Unique recipients are unpublished.

Is $243,697,582.31 the entire Biotech R&D (ex. Nano) USAspending total?

No. NAICS 541714's extract-wide total is $19,013,172,722.03. FY2026 is 1.3% of that book. Other fiscal-year rows for the same industry are separate cells. Do not add /industries/541714/ into this join. 2,378 award records stay on the industry extract, not on this yearlyTrend row.

Is $243,697,582.31 cash already paid in FY2026?

No. Obligations are commitments recorded on USAspending.gov awards. Outlays — money that actually left the Treasury — are a different concept and are not this packet's headline. Treating $243,697,582.31 as checks already cleared in FY2026 confuses those terms. Prefer the live industry and year hubs if the tables moved.

Where is the live Biotech R&D (ex. Nano)–FY2026 table?

/industries/541714/ is the industry parent and /fiscal-years/2026/ is the year parent. /industries/ covers every industry without the NAICS×year intersection as the headline. /ties/ lists other pairs. Those hubs are not addends. Keep both sides of the join when citing $243,697,582.31.